Skip to content

AARD AARD Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$1.56M+28.9%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$2.8M-1.0%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$15.86M+376%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$10.79M+8.7%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's change in accrued liabilities?
AARD (AARD) reported change in accrued liabilities of -$1.26M in Q1 2026.
How has AARD's change in accrued liabilities changed year-over-year?
AARD's change in accrued liabilities decreased by 189.4% year-over-year, from $1.41M to -$1.26M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.